- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01004575
Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease (KARE)
Clinical Evaluation of Kaname Cobalt-Chromium Coronary Stent System in the Treatment of Patients With Coronary Artery Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Current treatments for coronary artery disease include conservative treatment (drug therapies) and invasive techniques that help increase blood flow to ischemic or oxygen-deprived regions of the heart. Among the invasive techniques the most frequently used are coronary artery bypass graft surgery (CABG), and percutaneous transluminal coronary angioplasty (PTCA) without or with stents (bare metal stents (BMS) or drug eluting stents (DES)) implantation. However, all of those treatments have limitations and their effectiveness is diminished under certain circumstances. Therefore, it is essential to tailor therapy for each individual patient considering the overall patient's condition, disease severity and progression as well as concomitant diseases. The question of selection of appropriate stent for each individual patient is still unresolved and most of the physicians either follow international or national guidelines or scientific wisdom.
Although the efficacy of DES is undisputable in restenosis prevention, because some patients could have adverse outcomes from a DES, they should be used selectively in those who are most likely to benefit, and in that decision process several important issues should be addressed such as:Patients' adherence to post-stenting therapy, Bleeding risk, Need for elective surgery, Risk for restenosis, Risk for stent thrombosis. It is still believed that many patients will do well with BMSs and that this technology requires further refinements to improve outcome. For the above reasons Terumo has designed the new coronary BMS, Kaname™, a balloon expandable Cobalt-Chromium (CoCr) stent pre-mounted onto a high pressure, semi-compliant balloon on a rapid exchange delivery catheter. The Kaname stent is the subject of the current prospective, multi-centre KARE study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69677
- Hopital Cardiovasculaire et Pneumologie Louis Pradel
-
Nantes, France, 44035
- CHU Nord
-
Nimes, France, 30000
- Clinique Les Franciscaines
-
Paris CEDEX 05, France, 75230
- Hopital d'Instructions des Armées du Val de Grace
-
Toulouse CEDEX 9, France, 31059
- CHU Rangeuil
-
-
-
-
-
Fulda, Germany, 36043
- Klinikum Fulda gAG
-
Ludwigshafen, Germany, 67063
- Klinikum Ludwigshafen
-
Mainz, Germany, 55131
- Klinikum des Johannes Gutenberg Universität
-
-
-
-
-
Florence, Italy, 50141
- Ospedale Careggi
-
Milan, Italy, 20122
- Policlinico Milano
-
Palermo, Italy, 90100
- Ospedale Civico Palermo
-
-
-
-
-
Belgrade, Serbia, 11000
- Clinical Hospital Center Zemun
-
Belgrade, Serbia, 11000
- Clinical Centre of Serbia
-
Belgrade, Serbia, 11040
- Institute for Cardiovascular Disease Dedinje
-
-
-
-
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28046
- Hospital La Paz
-
Vigo, Spain, 36214
- Hospital Meixoeiro
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is ≥ 18 years old.
- Patient is eligible for PCI and acceptable candidate for CABG.
- Clinical evidence of ischemic heart disease and/or a positive functional study. Documented stable angina pectoris (CCS 1, 2, 3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or documented silent ischemia.
- The target lesion or target vessel meets all the following criteria;a) is a single de novo lesion or restenotic post-PTCA (non-stented) lesion in one native coronary artery.b)The stenosis of target lesion is ≥ 50% and < 100% c)The target lesion length must be ≤ 25 mm d)The target reference vessel diameter must be suitable for treatment with stents between 2.5 and 4.0 mm long
- Patient has been informed of the nature of the study, understands the study requirements and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.
- The patient is able to comply with all specified follow-up evaluations.
Exclusion Criteria:
- Most recent LVEF of the patient is < 25%.
- Known allergies to the following: aspirin, Clopidogrel bisulfate, Prasugrel or Ticlopidine, heparin, cobalt, chromium, nickel, or contrast agent (that cannot be adequately premedicated).
- A platelet count <100,000 cells/mm3 or >700,000 cells/mm3.
- WBC count < 3500 cells/mm3.
- Evidence of MI with positive Troponin within 72 hours of the intended treatment.
- Previous PCI (<30 days) anywhere within the target vessel.
- Planned interventional treatment of any non-target vessel <30 days post-procedure will be required. Planned intervention on the target vessel or on a significant lesion of > 50% stenosis anywhere within the target vessel after the index procedure will be required.
- The target lesion requires treatment with a device other than PTCA balloon prior to stent placement. (e.g. but not limited to directional coronary atherectomy, excimer laser, rotational atherectomy, etc.).
- Previous stenting anywhere within the target vessel.
- Target vessel has evidence of thrombus.
- Excessive tortuousity (> 60°) of the target vessel proximal to the target lesion (visual estimate).
- Either of the following characteristics in the target lesion (visual estimate): a)Ostial target lesion or bifurcation lesion b)Target lesion involves a side branch > 2mm in diameter c) Target lesion has excessive tortuousity (> 45°)d)Moderate to severely calcified lesion which can not be successfully predilated e)Target lesion is located in or supplied by an arterial or venous bypass graft f)Significant (> 40%) stenosis proximal or distal to the target lesion. g) A complete occlusion (TIMI flow 0 or 1).
- Target lesion located in left main trunk.
- Stroke or transient ischemic attack < prior 180 days.
- Active peptic ulcer or upper GI bleeding < prior 180 days.
- The patient has bleeding hemorrhagic diathesis or coagulopathy. The patient will refuse a blood transfusion.
- The patient has a widespread peripheral vascular disease.
- Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl).
- The patient requires multiple stent implantations for a tandem lesion.
- Life expectancy < 1 year.
- Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials.
- In the investigators opinion patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
- Patient is in cardiogenic shock.
- Female of child-bearing potential.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Kaname
patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
|
implantation of Kaname Cobalt-Chromium coronary stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from Target vessel failure TVF
Time Frame: 6 months post-procedure
|
Freedom from Target vessel failure TVF defined as composite of clinically driven target vessel revascularization (TVR)myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
|
6 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from TVF for patients treated with ≥ 3 mm stents.
Time Frame: 6 months post-procedure
|
Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel) for patients treated with ≥ 3 mm stents.
|
6 months post-procedure
|
Freedom from TVF for patients treated with 2.5 and 2.75 mm stents
Time Frame: 6 months post-procedure
|
Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel) for patients treated with 2.5 and 2.75 mm stents
|
6 months post-procedure
|
Freedom from TVF
Time Frame: 30 days,12 months and 3 and 5 years post-procedure
|
Freedom from Target Vessel Failure (composite of clinically driven TVR, myocardial infarction or cardiac death that could not be clearly attributed to a vessel other than the target vessel)
|
30 days,12 months and 3 and 5 years post-procedure
|
Clinically driven target lesion revascularization (TLR) free rate .
Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Clinically driven target lesion revascularization (TLR) free rate
|
30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Clinically driven target vessel revascularization (TVR) free rate.
Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Clinically driven target vessel revascularization (TVR) free rate.
|
30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Device success
Time Frame: Baseline procedure
|
Device success defined as achievement of a residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using the assigned device only.
|
Baseline procedure
|
Lesion success
Time Frame: Baseline procedure
|
Lesion success defined as the attainment of residual diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method.
|
Baseline procedure
|
Procedure success
Time Frame: During baseline hospital stay
|
Procedure success defined as achievement of a final diameter stenosis of < 50% by QCA or < 30% by visual estimate, using any percutaneous method, without MACE (composite of cardiac death, MI and TLR) .
|
During baseline hospital stay
|
Angiographic in-stent acute gain
Time Frame: Baseline procedure
|
Angiographic in-stent acute gain at the end of the procedure
|
Baseline procedure
|
Angiographic in-stent and in-segment binary restenosis rate (≥ 50%) diameter stenosis
Time Frame: 6 months post-procedure
|
Angiographic in-stent and in-segment binary restenosis rate (≥ 50%) diameter stenosis
|
6 months post-procedure
|
Angiographic in-stent, in-segment, proximal, and distal minimum lumen diameter (MLD)
Time Frame: 6 months post-procedure
|
Angiographic in-stent, in-segment, proximal, and distal minimum lumen diameter (MLD)
|
6 months post-procedure
|
In-stent late-loss
Time Frame: 6 months post-procedure
|
In-stent late-loss (as measured by QCA) defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up MLD.
|
6 months post-procedure
|
% Diameter Stenosis, in-stent and in-segment .
Time Frame: 6 months post-procedure
|
% Diameter Stenosis, in-stent and in-segment.
|
6 months post-procedure
|
Neointimal hyperplasia volume as measured by intravascular ultrasound.
Time Frame: 6 months post-procedure
|
Neointimal hyperplasia volume as measured by intravascular ultrasound at 6 months post-procedure
|
6 months post-procedure
|
Major adverse cardiac events (MACEs) rate .
Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Major adverse cardiac events (MACEs: composite of cardiac death,, myocardial infarction and TLR) rate.
|
30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Serious adverse event rate .
Time Frame: 30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Serious adverse event rate.
|
30 days, 6 and 12 months, 3 and 5 years post-procedure
|
Device failure .
Time Frame: Baseline procedure
|
Any device failure
|
Baseline procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Didier Carrie, Prof Dr, CHU Rangeuil, 31059 Toulouse, France
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- T111E4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on implantation of Kaname Cobalt-Chromium coronary stent
-
Cordis CorporationCompletedCoronary Artery DiseaseBelgium
-
Azienda Ospedaliero Universitaria Maggiore della...UnknownMyocardial Infarction | External Causes of Morbidity and Mortality | Fracture of Stent of Coronary Artery | Coronary Vessel DisordersItaly
-
Hospital Clinic of BarcelonaCompletedMyocardial Infarction | Infarction | Necrosis | Cardiovascular Diseases | Vascular Diseases | ST Elevation Myocardial Infarction | Heart DiseaseSpain, Italy, Netherlands
-
Spanish Society of CardiologyCompletedMyocardial InfarctionSpain, Italy, Netherlands
-
Rigshospitalet, DenmarkCompleted
-
OrbusNeichCompletedCoronary Artery Disease | Coronary Artery StenosisNetherlands, Belgium, United Kingdom, France, Germany, Austria
-
CID - Carbostent & Implantable DevicesCompletedMyocardial Ischemia | Coronary Stenosis | Coronary Artery Diseases | Coronary Atherosclerotic Disease | Coronary Occlusive DiseasesItaly
-
International Biomedical Systems S.p.A.UnknownCoronary Artery Disease | Angioplasty, Transluminal, Percutaneous Coronary | StentsGermany, Italy, Netherlands, Switzerland
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
Iwate Medical UniversityCompleted